Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Lordick, F., Carneiro, F., Cascinu, S., Fleitas, T., Haustermans, K., Piessen, G., Vogel, A., Smyth, E.C.
Published in Annals of oncology (01.10.2022)
Published in Annals of oncology (01.10.2022)
Get full text
Journal Article
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Lordick, F, Mariette, C, Haustermans, K, Obermannová, R, Arnold, D
Published in Annals of oncology (01.09.2016)
Published in Annals of oncology (01.09.2016)
Get full text
Journal Article
Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Obermannová, R., Alsina, M., Cervantes, A., Leong, T., Lordick, F., Nilsson, M., van Grieken, N.C.T., Vogel, A., Smyth, E.C.
Published in Annals of oncology (01.10.2022)
Published in Annals of oncology (01.10.2022)
Get full text
Journal Article
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
Sahin, U., Türeci, Ö., Manikhas, G., Lordick, F., Rusyn, A., Vynnychenko, I., Dudov, A., Bazin, I., Bondarenko, I., Melichar, B., Dhaene, K., Wiechen, K., Huber, C., Maurus, D., Arozullah, A., Park, J.W., Schuler, M., Al-Batran, S.-E.
Published in Annals of oncology (01.05.2021)
Published in Annals of oncology (01.05.2021)
Get full text
Journal Article
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
Türeci, O., Sahin, U., Schulze-Bergkamen, H., Zvirbule, Z., Lordick, F., Koeberle, D., Thuss-Patience, P., Ettrich, T., Arnold, D., Bassermann, F., Al-Batran, S.E., Wiechen, K., Dhaene, K., Maurus, D., Gold, M., Huber, C., Krivoshik, A., Arozullah, A., Park, J.W., Schuler, M.
Published in Annals of oncology (01.09.2019)
Published in Annals of oncology (01.09.2019)
Get full text
Journal Article
Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer
Peeters, M., Price, T.J., Cervantes, A., Sobrero, A.F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C.J.A., Strickland, A.H., Wilson, G., Ciuleanu, T.E., Roman, L., Van Cutsem, E., Tian, Y., Sidhu, R.
Published in Annals of oncology (01.01.2014)
Published in Annals of oncology (01.01.2014)
Get full text
Journal Article
Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial
Hacker, U.T., Hasenclever, D., Baber, R., Linder, N., Busse, H., Obermannova, R., Zdrazilova-Dubska, L., Valik, D., Lordick, F.
Published in Annals of oncology (01.07.2022)
Published in Annals of oncology (01.07.2022)
Get full text
Journal Article
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
Muro, K., Van Cutsem, E., Narita, Y., Pentheroudakis, G., Baba, E., Li, J., Ryu, M -H, Zamaniah, W I Wan, Yong, W -P, Yeh, K -H, Kato, K., Lu, Z., Cho, B.C., Nor, I.M., Ng, M., Chen, L -T, Nakajima, T.E., Shitara, K., Kawakami, H., Tsushima, T., Yoshino, T., Lordick, F., Martinelli, E., Smyth, E.C., Arnold, D., Minami, H., Tabernero, J., Douillard, J -Y
Published in Annals of oncology (01.01.2019)
Published in Annals of oncology (01.01.2019)
Get full text
Journal Article
Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas
Schmidt, T, Sicic, L, Blank, S, Becker, K, Weichert, W, Bruckner, T, Parakonthun, T, Langer, R, Büchler, M W, Siewert, J-R, Lordick, F, Ott, K
Published in British journal of cancer (02.04.2014)
Published in British journal of cancer (02.04.2014)
Get full text
Journal Article
Her2/neu testing in gastric cancer: evaluating the risk of sampling errors
Warneke, V.S., Behrens, H.-M., Böger, C., Becker, T., Lordick, F., Ebert, M.P.A., Röcken, C.
Published in Annals of oncology (01.03.2013)
Published in Annals of oncology (01.03.2013)
Get full text
Journal Article
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)
Moehler, M., Maderer, A., Thuss-Patience, P.C., Brenner, B., Meiler, J., Ettrich, T.J., Hofheinz, R.-D., Al-Batran, S.E., Vogel, A., Mueller, L., Lutz, M.P., Lordick, F., Alsina, M., Borchert, K., Greil, R., Eisterer, W., Schad, A., Slotta-Huspenina, J., Van Cutsem, E., Lorenzen, S.
Published in Annals of oncology (01.02.2020)
Published in Annals of oncology (01.02.2020)
Get full text
Journal Article